ProCE Banner Activity


Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients


On-demand webcast of expert faculty presentation and case discussion on new and emerging therapies for treating patients with low-risk myelodysplastic syndromes, including strategies for implementing guideline-recommended and individualized treatment plans. 

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 14, 2024

Expiration: December 13, 2024



Rami Komrokji

Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Maximilian Stahl

Maximilian Stahl, MD

Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This program is intended for hematologists, oncologists and other healthcare professionals treating patients with myelodysplastic syndromes.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in aligning clinical practice with evolving standards of care for patients with lower-risk myelodysplastic syndromes.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Plan first-line individualized therapeutic strategies for patients with LR-MDS based on new clinical data/approvals, new WHO and ICC guidelines, patient and disease characteristics, and validated risk stratification tools

  • Employ the latest approvals and recent clinical trial results on dosing frequency and escalation, and durability of response when considering treatment of patients with very low–risk, low-risk, or intermediate-risk MDS

  • Develop evidence-based and equitable care plans that recognize and identify early ESA treatment failure in all patients with LR-MDS

  • Appraise ongoing clinical trials evaluating newer agents and approaches for the treatment of patients with lower-risk MDS for appropriate and inclusive patient enrollment


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Rami Komrokji, MD

Section Head – Leukemia & MDS, Vice Chair
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Rami Komrokji, MD: consultant/advisor/speaker: AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Geron, Janssen, Jazz, Pharma Essentia, Rigel, Servio, Sobi, Sumitomo Pharma; researcher: Bristol Myers Squibb.

Maximilian Stahl, MD

Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Maximilian Stahl, MD: consultant/advisor/speaker: Bristol Myers Squibb, Curis, GlaxoSmithKline, Kymera, Rigel Pharmaceuticals, Sierra Oncology, Sobi.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 14, 2024, through December 13, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit to create your account.